Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Electronic Health Records Poised to Benefit Healthcare with New Partnerships

Electronic Health Records (EHR) Big Tech is teaming up with big tech to transform healthcare. Three giants in the electronic health record industry, Epic, Meditech, and Oracle Cerner, recently announced agreements with several Big Tech organizations and some tech startups to provide improved offerings to healthcare organizations. Epic entered into an agreement with Google Cloud,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Electronic Health Records (EHR) Big Tech is teaming up with big tech to transform healthcare.

Three giants in the electronic health record industry, Epic, Meditech, and Oracle Cerner, recently announced agreements with several Big Tech organizations and some tech startups to provide improved offerings to healthcare organizations.

Epic entered into an agreement with Google Cloud, enabling health systems to migrate their EHRs to the cloud. Meditech entered a similar partnership with Google. In addition, Meditech is integrating its platform with digital care company SeamlessMD.

Oracle Cerner partnered with life sciences company Labcorp to manage hospital-based laboratories in 10 states. This partnership allows Labcorp to standardize and optimize workflows for better efficiency and support information sharing.

If overcoming healthcare challenges, and improving the EHR process is the goal, then these announcements are sure to move the industry in a positive direction. David Kemp, Healthcare Lead at MarketScale, shares the industry’s enthusiasm about the partnerships.

David’s Thoughts

“So if you’ve been around healthcare long enough, you know interoperability is a big challenge. Exchanging data between systems is important for a lot of reasons, mainly to integrate that data to make better, smarter decisions for the patient to improve the patient outcome. But interoperability has always been a challenge, and so exciting news here is that Epic, arguably the largest electronic health record provider in the space is launching The Connection Hub on January 9th. It’s essentially a website where other vendors can prove and be documented or attain interoperability certification through Epic. This will allow providers, and other Epic users to come on and see what vendors they should use to maybe fill in some gaps or some holes in their functionality.

So I think this is a good step for the industry. I think it’s a good step for providers to be able to have access to that information and make smarter, easier, quicker decisions on what vendors to consider when evaluating during the sales process. But it’ll be interesting to see what Epic does with this data.

Now they get to see who has that integration built out in the space, what maybe features or functionalities they’re able to provide to the provider community, and maybe they start making decisions on what next features and functionalities they want to add to the Epic system. Ultimately, I think it’s a benefit for everybody.

It allows those vendors to get exposure to the providers that they want to work with. It gives the information to the providers when looking to fill gaps in their features and functionality, but Epic because they own the data might benefit the most. Overall, I think it’s a positive step in the right direction and uh, we’ll see what it really looks like on January 9th when Epic launches the Connection Hub.”

Article by James Kent

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512